Welcome to our dedicated page for Cibus SEC filings (Ticker: CBUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cibus, Inc.'s SEC filings document an agricultural biotechnology company that uses proprietary gene-editing technologies to develop plant traits for licensing to seed companies. The filings describe its royalty-oriented model, productivity traits for major agricultural food crops, and trait categories tied to weeds, pests, diseases, sustainability and yield challenges.
The company's regulatory record includes 8-K material-event reports, financial-results exhibits, proxy materials, governance disclosures and capital-structure information for its Class A common stock. These filings also cover board appointments, compensatory arrangements, shareholder voting matters, material agreements, registered securities and business disclosures related to the development and commercialization of gene-edited crop traits.
Cibus, Inc. chief legal officer Jason Stokes reported a routine tax-related share disposition. On March 30, 2026, 3,695 shares of Class A Common Stock were withheld at a weighted average price of $1.83 per share to cover tax obligations. The withheld shares came from multiple trades priced between $1.81 and $1.88. After this transaction, Stokes directly held 110,865 shares of Cibus common stock.
Cibus, Inc. CFO Broos Carlo reported a tax-related share disposition. On this Form 4, 3,676 shares of Class A Common Stock were disposed of at a weighted average price of $1.87 per share to satisfy tax obligations by delivering securities. After this transaction, Carlo directly holds 97,275 shares.
This was a tax-withholding disposition tied to equity compensation rather than an open-market trade, so it functions as an administrative event and does not reflect an active buy or sell decision on the open market.
Cibus, Inc. Chief Scientific Officer and EVP Gregory Francis William Gocal reported a routine tax-withholding disposition of 8,954 shares of Class A Common Stock. The shares were applied at a weighted average price of $1.82 per share. After this transaction, he directly holds 365,890 shares of Cibus common stock.
Cibus, Inc. director and interim CEO, president and COO Peter Beetham reported a tax-withholding disposition of 16,112 shares of Class A Common Stock on March 30, 2026. The weighted average price was $1.85 per share, with trades ranging from $1.81 to $2.10. Following this withholding to cover obligations, he directly holds 491,825 shares, indicating this was a routine compensation-related event rather than an open-market sale.
Cibus, Inc. entered an underwriting agreement with BTIG, LLC for an underwritten public offering of 6,976,744 shares of Class A common stock at $2.15 per share. The company expects net proceeds of about $13.5 million, or $16.0 million if the 1,046,511-share overallotment option is fully exercised.
The offering is expected to close on or about March 27, 2026, subject to customary conditions, under a previously effective Form S-3 shelf registration. The underwriter will receive a 7.0% discount on gross proceeds, and directors, officers and the company agreed to a 60-day lock-up on additional sales, with customary exceptions.
Cibus, Inc. is offering 6,976,744 shares of Class A Common Stock at $2.15 per share. The offering includes a 30-day underwriter option to purchase up to an additional 1,046,511 shares and is expected to deliver on or about March 27, 2026. Net proceeds are estimated at approximately $13.5 million (or approximately $16.0 million if the option is exercised in full).
The company intends to use proceeds for working capital and to fund further development of its Rice weed management traits. Financial context disclosed: as of December 31, 2025, Cibus reported $9.9 million in cash and cash equivalents and $16.9 million in current liabilities, and the audit report contains a going concern explanatory paragraph.
Cibus, Inc. is offering shares of its Class A Common Stock and pre-funded warrants pursuant to a preliminary prospectus supplement dated March 25, 2026. The offering is being sold on a firm commitment underwritten basis with a 30-day option for additional shares.
The filing discloses $9.9 million of cash and cash equivalents and $16.9 million of current liabilities as of December 31, 2025, and states there is substantial doubt about Cibus’ ability to continue as a going concern without additional financing. The company intends to use net proceeds for working capital and continued development of its Rice herbicide tolerance traits.
Cibus, Inc. CFO Carlo Broos reported a small share disposition related to tax withholding. On this Form 4, 1,496 shares of Class A Common Stock were surrendered at $1.32 per share to cover tax obligations rather than sold on the open market. After this transaction, he directly holds 100,951 shares, so his overall ownership stake remains largely unchanged.
Cibus, Inc. senior vice president of research Noel Sauer reported two transactions in Class A common stock. On November 11, 2025, 1,834 shares were disposed of at $1.32 per share as a tax-withholding transaction, rather than an open-market trade. Earlier, on June 13, 2025, Sauer completed a small open-market sale of 4 shares at $1.485 per share. Following these transactions, Sauer directly holds 103,642 shares of Cibus Class A common stock.
Cibus, Inc. executive Jason Stokes, the company’s CLO, General Counsel and Secretary, reported routine share dispositions tied to tax obligations. Across three Form 4 entries using code F, a total of 13,109 Class A common shares were withheld to cover taxes, and he now holds 114,560 shares directly after the most recent transaction.